AviadoBio is focusing on neurodegenerative diseases and has emerged from stealth with nearly $100m in total from investors including Johnson & Johnson Innovation – JJDC.

UK-based neurodegenerative gene therapy developer AviadoBio picked up $80m yesterday in a series A round featuring Johnson & Johnson Innovation – JJDC, a subsidiary of medical product group Johnson & Johnson

The round was co-led by New Enterprise Associates and Monograph Capital and included investment and financial services group Fidelity’s F-Prime Capital subsdidiary, LSP, Advent Life Sciences, Dementia Discovery Fund (DDF) and LifeArc.

Founded in 2019, AviadoBio is working on gene therapies for neurodegenerative conditions including frontotemporal dementia (FTD) and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn